ICIsabella O. Conway

Isabella O. Conway

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Isabella O. Conway has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dysbiosis-induced expansion of AXL-positive inflammatory type 3 dendritic cells triggers preclinical autoimmunity

    by Grozdan Cvijetic, Valentina Ottaviani, Isabella O. Conway, Erfan Jabari, Mladen Mitrovic, Haiting Wang, Patrick Fernandes Rodrigues, Anastasia du Halgouet, Siqi Zhao, Harrison C. Wang, et al.

    Conventional dendritic cells (cDCs) are key sentinels at epithelial barriers, regulating immunity to microbial pathogens and commensals while preserving tissue integrity. NOTCH2 deficiency in CD11c-expressing cells ( Notch2 cKO ) disrupts type 2a DC (cDC2a) development, impairs intestinal T H 17 immunity and increases susceptibility to enteropathogenic bacteria. This defect leads to persistent dysbiosis in Notch2 cKO mice, characterized by low-grade inflammation and systemic autoimmune features, including elevated autoantibody titers and renal immune complex deposition. Dysbiosis precedes expansion of highly inflammatory AXL-expressing type 3 DCs (AXL + inf-DC3), promoting chronic inflammation and tertiary lymphoid structures driving adaptive immune responses. Notably, dysbiosis is defined by three dominant pathobionts and is transferable to wild-type mice, recapitulating the autoimmune features observed in Notch2 cKO mice. Here these findings identify a microbiota–DC axis linking intestinal pathobionts to systemic autoimmunity, establishing inflammatory DC3 as the cellular bridge between dysbiosis, chronic inflammation and autoimmune pathogenesis.


  • A parasite partner for regulatory affairs

    by Isabella O. Conway, Christopher A. Hunter

    Targeting Treg cells to mitigate inflammation has been a challenge, but a parasite-derived cytokine may be key to engineering a Treg cell therapy.

  • Open Access

    IL-27 promotes Treg cell expression of CD122 and fitness at homeostasis

    by Zachary R. Lanzar, Daniel L. Aldridge, Elisa Cruz-Morales, Christian A. Howard, Isabella O. Conway, Zhe Zhong, Julia N. Eberhard, Joseph A. Pereira, Anthony T. Phan, Aaron M. Ring, et al.

    Regulatory T (Treg) cells express high levels of the IL-27R, and in the setting of infection and autoimmunity, the cytokine IL-27 promotes Treg cell activities that mitigate tissue pathology. However, IL-27 appears dispensable for Treg cell development and maintenance as lineage-specific depletion of the IL-27R on Treg cells does not impact these populations at steady state. In contrast, when mice were generated in which the Treg compartment comprised a mix of IL-27R-sufficient and -deficient Treg cells, those that lacked IL-27R were at a competitive disadvantage. Aging experiments illustrate that IL-27R-deficient Treg cells are preferentially eroded, and this defect was associated with reduced expression of CD122, the β chain of the IL-2/15R. Moreover, blockade of CD122 led to a similar loss of Treg cells, and in vitro and in vivo studies highlight that IL-27 promotes Treg cell expression of CD122 and improves responsiveness to IL-2/15. These datasets reveal that homeostatic IL-27 signals provide a competitive advantage that shapes the composition of the Treg cell pool by modulating responsiveness to growth factors.


  • Open Access

    Structures of TGF-β with betaglycan and the signaling receptors reveal the mechanism whereby betaglycan potentiates receptor complex assembly and signaling

    by Łukasz Wieteska, Alexander B. Taylor, Emma Punch, Jonathan A. Coleman, Isabella O. Conway, Yeu-Farn Lin, Chang-Hyeock Byeon, Cynthia S. Hinck, Troy Krzysiak, Rieko Ishima, et al.

    Betaglycan (BG) is a transmembrane co-receptor of the transforming growth factor-β (TGF-β) family of signaling ligands. It is essential for embryonic development and tissue homeostasis and fertility in adults. It functions by enabling binding of the three TGF-β isoforms to their signaling receptors and is additionally required for inhibin A (InhA) activity. Despite its requirement for the functions of TGF-βs and InhA in vivo, structural information explaining BG ligand selectivity and its mechanism of action is lacking. Here, we determine the structure of TGF-β bound both to BG and the signaling receptors, TGFBR1 and TGFBR2. We identify key regions responsible for ligand engagement, which has revealed novel binding interfaces that differ from those described for the closely related co-receptor of the TGF-β family, endoglin, thus demonstrating remarkable evolutionary adaptation to enable ligand selectivity. Finally, we provide a structural explanation for the hand-off mechanism underlying TGF-β signal potentiation.